Androgen receptor in breast cancer: The “5W” questions

Androgen receptor (AR) is expressed in 60-70% of breast cancers (BCs) and the availability of anti-AR compounds, currently used for treating prostate cancer, paves the way to tackle specifically AR-positive BC patients. The prognostic and predictive role of AR in BC is a matter of debate, since the...

Full description

Bibliographic Details
Published in:Frontiers in Endocrinology
Main Authors: Sara Ravaioli, Roberta Maltoni, Barbara Pasculli, Paola Parrella, Anna Maria Giudetti, Daniele Vergara, Maria Maddalena Tumedei, Francesca Pirini, Sara Bravaccini
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Subjects:
anti-AR therapy
AR/ER ratio
AR biomarker
AR signaling
breast cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2022.977331/full

Internet

https://www.frontiersin.org/articles/10.3389/fendo.2022.977331/full

Similar Items